Literature DB >> 15701675

Quality of life in patients with latex allergy.

Sultan Al-Otaibi1, Susan M Tarlo, Ronald House.   

Abstract

BACKGROUND: Exposure to natural rubber latex (NRL) may lead to a variety of allergic clinical manifestations that may affect the quality of life (QOL). AIM: To assess QOL of patients with different clinical effects of NRL allergy including rhino-conjunctivitis, asthma, anaphylaxis and skin manifestations.
METHOD: A questionnaire to assess QOL was mailed to 56 patients who had been assessed and managed for various clinical manifestations of latex allergy at a university affiliated hospital in Toronto, Canada.
RESULTS: Thirty-one questionnaires were completed and returned. Thirty of the respondents were health care workers. Forty-one percent of the respondents had changed their jobs to reduce exposure to latex and 13% had stopped working. However the respondents did not report a great effect on the QOL related to latex allergy.
CONCLUSION: The results of this study indicate that the various clinical manifestations of latex allergy can be managed so that there is no significant interference with QOL.

Entities:  

Mesh:

Year:  2005        PMID: 15701675     DOI: 10.1093/occmed/kqi001

Source DB:  PubMed          Journal:  Occup Med (Lond)        ISSN: 0962-7480            Impact factor:   1.611


  3 in total

1.  Quality of life of adults with workplace exacerbation of asthma.

Authors:  Elizabeth P Lowery; Paul K Henneberger; Richard Rosiello; Susan R Sama; Peggy Preusse; Don K Milton
Journal:  Qual Life Res       Date:  2007-10-24       Impact factor: 4.147

Review 2.  Asthma in the workplace: a Canadian contribution and perspective.

Authors:  Jean-Luc Malo; Moira Chan-Yeung
Journal:  Can Respir J       Date:  2007-10       Impact factor: 2.409

3.  Outcome of occupational latex allergy--work ability and quality of life.

Authors:  Albert Nienhaus; Kathrin Kromark; Monika Raulf-Heimsoth; Vera van Kampen; Rolf Merget
Journal:  PLoS One       Date:  2008-10-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.